«FAZA» is a project company, developing an innovative biological drug for chronic inflammatory and autoimmune diseases. The new drug is based on a human recombinant protein (an enzyme of hydrolase class), produced using different producer cells (including bacterial and plant cells). The drug inactivates the main inflammation triggers (lipopolysaccharides, ATP, etc.), disrupting the signal pathways underlying the pathogenesis of inflammatory and autoimmune diseases. «FAZA» is a participant of Skolkovo Innovation Center. Currently, technology optimization and preliminary studies of pilot batches of the drug are ongoing.